Nova Eye Medical Announces Q1 Results and FY26 Guidance
Nova Eye Medical Limited (ASX:EYE), a medical technology company, announced its Q1 results and provided guidance for FY26.
The company reported a revenue of US$4.854 million, a 20% increase compared to the prior corresponding period.
- Sales growth driven by strong performance in the US and Germany.
- Direct markets contributed significantly to overall revenue.
The company's leading product is iTrack Advance, a minimally invasive glaucoma surgical device with approvals in major global markets.
Nova Eye Medical held an investor webinar to discuss the announcement details.
Author's summary: Nova Eye Medical reports 20% revenue growth.
More News
- Anne Donnelly defeats Nicole Aloise in race for Nassau DA
- Bridget Phillipson must not abandon special needs children | The Spectator Australia
- Suffolk voters [reject/approve] ballot measure extending length of county legislative terms
- Democrats pick up seats in both Suffolk and Nassau legislatures
- Famous birthdays for Nov. 5: Kris Jenner, Tilda Swinton - UPI.com
- Supermicro's cash flow turns negative as AI infrastructure push strains finances
- Mamdani prevails in New York City mayoral race
- Vintage Blakeman – your man in NYC
- Nov 5: Primark could be spun off; Workplace sickness crisis; Peugeot Polygon concept
- The story LI's election numbers tell so far